|Day Low/High||4.55 / 4.72|
|52 Wk Low/High||2.95 / 6.23|
Grade "A" assigned to colorectal cancer screening exams by United States Preventive Services Task Force
Momentum reflects response to state mandated breast density notifications and healthcare provider confidence in iCAD's radiology workflow solution platform
iCAD, Inc., (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the identification and treatment of cancer, today announced that its mammography Computer...
Company highlights new SMART solution designed to enhance workflow efficiency, flexibility, safety and security of the Xoft System
Workflow tools offer significant productivity and efficiency
Acquisition expands iCAD's presence as the largest independent provider of mammography computer aided detection and workflow solutions and augments deep learning capabilities
Increased Global Demand for Leading-Edge Cancer Treatment Drives Adoption of Eight Xoft Systems for Intraoperative Radiation Therapy (IORT), Offering Significant Benefits to Patients and Clinicians
iCAD announces more than 2,000 early-stage breast cancer patients treated with the one-day breast cancer treatment
iCAD will demonstrate iReveal breast density assessment for 2D and tomosynthesis* mammography, PowerLook® Advanced Mammography Platform, and VeraLook colon polyp detection technology
Clinical research following patients up to five years indicates positive outcomes and few recurrences
One-day targeted radiation treatment for early-stage breast cancer honored as a top health innovation
iCAD to feature in-booth clinician presentations and showcase latest in technology during meeting.
Multi-platform campaign will highlight latest findings on adoption, appropriate patient selection, patient outcomes and other topics
New Leadership Will Contribute to the Continued Growth of the Cancer Detection Business
These under-$10 stocks are within range of triggering breakout trades.